Translational research in head and neck cancer: Molecular and immunological updates.

[1]  T. Tsuzuki,et al.  Immune Status of Cervical Lymph Nodes in Head and Neck Cancer—A Surgical Oncology Perspective , 2023, Journal of personalized medicine.

[2]  M. Takahara,et al.  Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer , 2023, Cancer Immunology, Immunotherapy.

[3]  P. Castle.  Prophylactic Human Papillomavirus Vaccination for Prevention of Oropharyngeal Cancer in Older Men: Is the Juice Worth the Squeeze? , 2023, Journal of the National Cancer Institute.

[4]  Ying Wang,et al.  Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy , 2023, Signal Transduction and Targeted Therapy.

[5]  E. Vogtmann,et al.  Oral microbiome and risk of incident head and neck cancer: A nested case-control study. , 2023, Oral oncology.

[6]  T. Seiwert,et al.  Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Ferris,et al.  Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment , 2022, Nature Reviews Cancer.

[8]  S. Takeda,et al.  Tumor-derived exosomes elicit cancer-associated fibroblasts shaping inflammatory tumor microenvironment in head and neck squamous cell carcinoma. , 2022, Oral oncology.

[9]  H. Wakiyama,et al.  Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response , 2022, Oncoimmunology.

[10]  N. Hanai,et al.  Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer , 2022, Cancers.

[11]  M. R. Fernandes,et al.  Targeting the gut microbiota for cancer therapy , 2022, Nature Reviews Cancer.

[12]  H. Wakiyama,et al.  Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts. , 2022, Molecular cancer therapeutics.

[13]  Anders B. Dohlman,et al.  A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors , 2022, Cell.

[14]  C. Furdui,et al.  A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers , 2022, Cancers.

[15]  G. Krempl,et al.  Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival. , 2022, Oral oncology.

[16]  C. Sears,et al.  The microbiota and radiotherapy for head and neck cancer: What should clinical oncologists know? , 2022, Cancer treatment reviews.

[17]  C. Borg,et al.  A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study , 2022, Frontiers in Oncology.

[18]  Chongzhe Yang,et al.  Multi-Omics Integration Reveals the Crucial Role of Fusobacterium in the Inflammatory Immune Microenvironment in Head and Neck Squamous Cell Carcinoma , 2022, Microbiology spectrum.

[19]  Jinyan Liu,et al.  Intratumor microbiome in cancer progression: current developments, challenges and future trends , 2022, Biomarker research.

[20]  Brady Bernard,et al.  PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors , 2022, The Journal of clinical investigation.

[21]  Xu Wang,et al.  Candida albicans Induces Up-regulation of Programmed Death Ligand 1 in Oral Squamous Cell Carcinoma. , 2022, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[22]  Yu Zhang,et al.  Antibody drug conjugate: the “biological missile” for targeted cancer therapy , 2022, Signal Transduction and Targeted Therapy.

[23]  Jiang Li,et al.  EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma , 2022, Frontiers in Immunology.

[24]  A. Deneka,et al.  Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Y. Okada,et al.  OMARU: a robust and multifaceted pipeline for metagenome-wide association study , 2022, NAR genomics and bioinformatics.

[26]  Michihisa Kono,et al.  Antitumor Peptide-Based Vaccine in the Limelight , 2022, Vaccines.

[27]  X. Qu,et al.  Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes. , 2021, Oral oncology.

[28]  S. Tomida,et al.  Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment , 2021, JCI insight.

[29]  M. Biel,et al.  Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma , 2021, Head & neck.

[30]  Mitsuo Sato,et al.  Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[31]  P. Choyke,et al.  Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models , 2021, Molecular Cancer Therapeutics.

[32]  Y. Kawasaki,et al.  Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma , 2021, PloS one.

[33]  Christopher C. Griffith,et al.  Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer , 2021, Nature.

[34]  S. Yom,et al.  Head and neck cancer , 2021, The Lancet.

[35]  Y. Okada,et al.  Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese , 2021, Annals of the Rheumatic Diseases.

[36]  T. Tsuzuki,et al.  Improving function of cytotoxic T‐lymphocytes by transforming growth factor‐β inhibitor in oral squamous cell carcinoma , 2021, Cancer science.

[37]  M. Biel,et al.  A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma , 2021, International Journal of Clinical Oncology.

[38]  Jie Wu,et al.  Worldwide trend in human papillomavirus–attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030 , 2021, Cancer.

[39]  P. Choyke,et al.  Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials , 2021, EBioMedicine.

[40]  L. Ding,et al.  Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma , 2021, Oncotarget.

[41]  P. Choyke,et al.  Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity , 2021, Advanced therapeutics.

[42]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[43]  P. Boscolo-Rizzo,et al.  Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2021, Cancers.

[44]  A. Egloff,et al.  Integrating CD4+ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model , 2021, Oncoimmunology.

[45]  Y. Okada,et al.  A Metagenome-Wide Association Study of Gut Microbiome in Patients With Multiple Sclerosis Revealed Novel Disease Pathology , 2020, Frontiers in Cellular and Infection Microbiology.

[46]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[47]  Lixia Huang,et al.  Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure , 2020, Scientific Reports.

[48]  J. Hatazawa,et al.  Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan(10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[49]  A. Hauschild,et al.  Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. , 2020, The New England journal of medicine.

[50]  Kaoru Tanaka,et al.  Immunotherapy for squamous cell carcinoma of the head and neck. , 2020, Japanese journal of clinical oncology.

[51]  Zachary L. Skidmore,et al.  Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial , 2020, Clinical Cancer Research.

[52]  Hisataka Kobayashi,et al.  Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin , 2020, Cells.

[53]  Jennifer D. Oduro,et al.  Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection , 2020, Nature Immunology.

[54]  Anne-Claude Gingras,et al.  Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling , 2020, Science.

[55]  K. Nakao,et al.  YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma , 2020, Science Advances.

[56]  Jing Wang,et al.  Loss of p53 drives neuron reprogramming in head and neck cancer , 2020, Nature.

[57]  Y. Okamoto,et al.  Stratification of HPV‐associated and HPV‐negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes , 2020, International journal of cancer.

[58]  Thea D. Tlsty,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[59]  R. Motzer,et al.  Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. Choyke,et al.  Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models , 2020, Cancer Immunology Research.

[61]  Chen Ping Zhang,et al.  The Oral Microbiota May Have Influence on Oral Cancer , 2020, Frontiers in Cellular and Infection Microbiology.

[62]  M. Kupferman,et al.  Endoscopic resection of sinonasal malignancies , 2019, Head & neck.

[63]  Y. Okada,et al.  Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population , 2019, Annals of the rheumatic diseases.

[64]  P. Choyke,et al.  The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near Infrared Photoimmunotherapy (NIR-PIT). , 2019, Bioconjugate chemistry.

[65]  P. Choyke,et al.  Near-Infrared Photoimmunotherapy of Cancer , 2019, Accounts of chemical research.

[66]  Chin-Lee Wu,et al.  Expression of PD‐L1 in tumor‐associated nerves correlates with reduced CD8+ tumor‐associated lymphocytes and poor prognosis in prostate cancer , 2019, International journal of cancer.

[67]  Hisataka Kobayashi,et al.  Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma , 2019, Cancer biology & therapy.

[68]  P. Agius,et al.  Immunogenic neoantigens derived from gene fusions stimulate T cell responses , 2019, Nature Medicine.

[69]  Yusuke Nakamura,et al.  Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma , 2019, Oncoimmunology.

[70]  M. Quintanilla,et al.  Podoplanin in Inflammation and Cancer , 2019, International journal of molecular sciences.

[71]  P. Choyke,et al.  Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors , 2019, Cancer Immunology Research.

[72]  M. Tonogi,et al.  Feasibility of carbon‐ion radiotherapy for oral non‐squamous cell carcinomas , 2019, Head & neck.

[73]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[74]  D. Ye,et al.  The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis , 2018, Cellular Physiology and Biochemistry.

[75]  K. Woltjen,et al.  In vivo reprogramming drives Kras-induced cancer development , 2018, Nature Communications.

[76]  J. Paramio,et al.  Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. , 2018, Oral oncology.

[77]  Laurence Zitvogel,et al.  The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies , 2018, Science.

[78]  Ruud H. Brakenhoff,et al.  The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.

[79]  R. Hayes,et al.  Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer , 2018, JAMA oncology.

[80]  Songzhu Zhao,et al.  Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer , 2018, The Laryngoscope.

[81]  D. Saranath,et al.  High-Risk Human Papillomavirus in Oral Cancer: Clinical Implications , 2017, Oncology.

[82]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[83]  P. Frenette,et al.  Adrenergic nerves activate an angio-metabolic switch in prostate cancer , 2017, Science.

[84]  Emma Shanks,et al.  3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes , 2017, The FEBS journal.

[85]  Sung-Bae Kim,et al.  Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial , 2017, Thyroid : official journal of the American Thyroid Association.

[86]  T. Petrova,et al.  Microenvironmental regulation of tumour angiogenesis , 2017, Nature Reviews Cancer.

[87]  Aleksandra A. Kolodziejczyk,et al.  Dysbiosis and the immune system , 2017, Nature Reviews Immunology.

[88]  Peter L. Choyke,et al.  Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity , 2017, Oncotarget.

[89]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[90]  Su Jin Heo,et al.  PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.

[91]  S. Kolev,et al.  Candida virulence and ethanol-derived acetaldehyde production in oral cancer and non-cancer subjects. , 2016, Oral diseases.

[92]  J. Lee,et al.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells , 2016, Oncoimmunology.

[93]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[94]  P. Choyke,et al.  Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy , 2016, Science Translational Medicine.

[95]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[96]  S. Do,et al.  Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma , 2016, Laboratory Investigation.

[97]  Fan Wang,et al.  Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. , 2016, Biomaterials.

[98]  A. Shiotani,et al.  Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma , 2015, PloS one.

[99]  E. Celis,et al.  Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma , 2015, Scientific Reports.

[100]  S. Rokudai,et al.  Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma , 2015, Cancer Immunology, Immunotherapy.

[101]  F. Jalilian,et al.  The prevalence rate of Porphyromonas gingivalis and its association with cancer: A systematic review and meta-analysis , 2015, International journal of immunopathology and pharmacology.

[102]  Xiaobo Zhou,et al.  Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors , 2015, Epigenetics.

[103]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[104]  T. Sharpton.  An introduction to the analysis of shotgun metagenomic data , 2014, Front. Plant Sci..

[105]  E. Celis,et al.  EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy , 2013, British Journal of Cancer.

[106]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[107]  C. McConkey,et al.  Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region , 2013, Head & neck.

[108]  Katsumasa Takahashi,et al.  Immunosuppressive activity of CD14+ HLA‐DR− cells in squamous cell carcinoma of the head and neck , 2012, Cancer science.

[109]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[110]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[111]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[112]  Yoko Takahashi,et al.  Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro , 2011, Clinical Cancer Research.

[113]  F. Stickel,et al.  Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism , 2010, Genes & Nutrition.

[114]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[115]  M. Takahara,et al.  Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. , 2008, Cancer research.

[116]  T. Whiteside,et al.  The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[117]  T. Whiteside,et al.  Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck , 2007, Head & neck.

[118]  T. Omori,et al.  Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. , 2006, Carcinogenesis.

[119]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[120]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[121]  C. J. Chen,et al.  Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. , 2001, The New England journal of medicine.

[122]  G. Grillone,et al.  Head and Neck Cancer Screening Among 4611 Tobacco Users Older than Forty Years , 1997, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[123]  OUP accepted manuscript , 2022, The Oncologist.

[124]  V. Dellarco.  A mutagenicity assessment of acetaldehyde. , 1988, Mutation research.